Summary by Futu AI
Xinrui Pharmaceuticals International Holdings Limited (Xinrui Pharmaceuticals) has released its interim financial report up to June 30, 2024. The report shows that the group's revenue was approximately 16,718,000 Hong Kong dollars, a year-on-year decrease of about 46.1%. The owner's attributable net loss was approximately 4,088,000 Hong Kong dollars, a decrease of about 69.4% from the same period last year. The board does not recommend the distribution of any interim dividends. The asset liability ratio is zero, and the group did not have any bank or other borrowings during the reporting period. Xinrui Pharmaceuticals acquired 16% of the equity of China Nuwa Pharmaceuticals Group Co., Ltd. on May 16, 2024 for a consideration of 17,280,000 Hong Kong dollars. In addition, the group also acquired shares of Jiangxi Yimai Yangguang Group as a cornerstone investor. During the reporting period, the group did not engage in the purchase, sale, or redemption of any listed securities. The group currently has no future plans for significant investments, nor is it involved in any significant litigation, arbitration, or claims.
